abstract |
This invention relates to crystalline forms of [4- carbamoyl-1- (3- fluorobenzyl) -2, 7-dihydroxy-7-methyl-octyl] -amide of the quinoxaline-2-carboxylic acid, useful in the treatment or prevention of a disorder or condition through CCRI receptor antagonization, and its methods of preparation and use. |